Efficacy of antidepressants over placebo is similar in two-armed versus three-armed or more-armed randomized placebo-controlled trials
暂无分享,去创建一个
T. Furukawa | A. Cipriani | G. Salanti | L. Atkinson | Y. Ogawa | N. Takeshima | Y. Hayasaka | Shiro Tanaka
[1] T. Furukawa,et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis , 2016, BMJ Open.
[2] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .
[3] Nicky J Welton,et al. Evaluating novel agent effects in multiple‐treatments meta‐regression , 2010, Statistics in medicine.
[4] A. Kiss,et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. , 2010, The Journal of clinical psychiatry.
[5] J. Geddes,et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.
[6] Maurizio Fava,et al. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD , 2009, European Neuropsychopharmacology.
[7] John M. Davis,et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.
[8] R. Rosenthal,et al. Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.
[9] T. Furukawa,et al. Imputing response rates from means and standard deviations in meta-analyses , 2005, International clinical psychopharmacology.
[10] Russell L. Kolts,et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. , 2004, The American journal of psychiatry.
[11] M. Hotopf,et al. "Wish Bias" in Antidepressant Drug Trials? , 2004, Journal of clinical psychopharmacology.
[12] S. Wessely,et al. Active placebos versus antidepressants for depression. , 2004, The Cochrane database of systematic reviews.
[13] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[14] R. Dardennes,et al. Critical approach to antidepressant trials. Blindness protection is necessary, feasible and measurable. , 2000, The British journal of psychiatry : the journal of mental science.
[15] R. Bornstein,et al. A meta-analysis of antidepressant outcome under "blinder" conditions. , 1992, Journal of consulting and clinical psychology.
[16] A Ehlers,et al. How "blind" are double-blind studies? , 1991, Journal of consulting and clinical psychology.
[17] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[18] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.